$290,000 of STRYKER CORPORATION lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing. This ...

HUTCHMED announced positive results from the global Phase III SAFFRON trial, demonstrating that the combination of ORPATHYS® ...

U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat: ...

Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial on October 26, 2026.

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization ...

Reps. Zoe Lofgren and George Whitesides said they introduced the “SHIELD Our Elections Act,” a bill aimed at “protect[ing] ...

OpenWorld confirms its dual listing on Figure OPEN is set for Q4 2026, enhancing trading options for shareholders.

As announced on October 1, 2026, OpenWorld is pursuing a dual listing on Figure OPEN, building on its previously announced agreement with Figure Technology Solutions, Inc. (NASDAQ: FIGR) to offer a ...

NovaBridge Biosciences announced updated results from the Phase 1b study of givastomig, a bispecific antibody targeting ...

Rep. Steny Hoyer says he has asked the House and Senate Armed Services committees to investigate reports of restrictions on ...